Completed PHASE3 INTERVENTIONAL NCT00073580

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-PUMP CABG

Sponsor: The Medicines Company

Conditions Cardiac Disease Coronary Artery Bypass Surgery Thrombocytopenia Thrombosis

Interventions Angiomax (bivalirudin) anticoagulant

Updated 7 times since 2017 Last updated: Nov 29, 2018 Started: Oct 31, 2003 Primary completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00073580, this PHASE3 trial focuses on Cardiac Disease and Coronary Artery Bypass Surgery and remains completed. Sponsored by The Medicines Company, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jun 2018 — Dec 2018 [monthly]

Unknown Status PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Medicines Company

Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States